Piper Sandler Downgrades Acceleron Pharma to Neutral, Raises Price Target to $180
Piper Sandler analyst Christopher Raymond downgrades Acceleron Pharma (NASDAQ:XLRN) from Overweight to Neutral and raises the price target from $146 to $180.
SVB Leerink Maintains Market Perform on Acceleron Pharma, Raises Price Target to $180
SVB Leerink analyst Geoffrey Porges maintains Acceleron Pharma (NASDAQ:XLRN) with a Market Perform and raises the price target from $148 to $180.
Merck Seals Acceleron Pharma Deal For $180/Share: Highlights
Putting all the speculations at bay, Merck & Co Inc (NYSE:MRK) has agreed to acquire Acceleron Pharma Inc (NASDAQ:XLRN) for $180 per share…
Merck To Acquire Acceleron Pharma For $180/Share In Cash For An Approximate Total Equity Value Of $11.5B
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Acceleron Pharma Inc. (NASDAQ:XLRN), a publicly traded biopharmaceutical company, today announced that the companies have entered into a definitive
The Daily Biotech Pulse: AbbVie’s Migraine Drug OK’d By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours.
Click here for accessing Benzinga's FDA Calendar
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 28)
Notable Acceleron Pharma Insider Trades $1.08 Million In Company Stock
Sujay Kango, EVP And Chief Commercial Officer at Acceleron Pharma (NASDAQ:XLRN), made a large buy and sell of company shares on September 27, according to a new SEC filing.
Benzinga Pro’s Top 5 Stocks To Watch For Tuesday, Sept. 28, 2021: XLRN, TSLA, DBGI, ANY, CEI
Today's 5 Stock Ideas:
Acceleron Pharma (XLRN) - A WSJ report late Monday suggested Merck (MRK) was near a deal to buy Acceleron. Shares were relatively quiet Tuesday morning, up
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer’s Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 27)
Merck Reportedly Lead Bidder In $11B Acceleron Buyout: WSJ
The Wall Street Journal reported that Merck & Co Inc (NYSE:MRK) is in advanced talks to acquire Acceleron Pharma Inc (NASDAQ:XLRN), citing people familiar…